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Available online 12 May 2016Acute lung injury/acute respiratory distress syndrome (ALI/ARDS) is a major cause of global morbidity andmor-
tality. Mesenchymal stem cells (MSC) have shown promise in treating inﬂammatory lung conditions. We
hypothesised that humanMSC (hMSC) can improve ALI/ARDS through their anti-inﬂammatory actions. We sub-
jected pigs (n= 6) to intravenous oleic acid (OA) injury, ventilation and hMSC infusion, while the controls (n=
5) had intravenous OA, ventilation and an infusion vehicle control. hMSC were infused 1 h after the administra-
tion of OA. The animals were monitored for additional 4 h. Nuclear translocation of nuclear factor-light chain en-
hancer of activated B cells (NF-κB), a transcription factor that mediates several inﬂammatory pathways was
reduced in hMSC treated pigs compared to controls (p=0.04). Therewas no signiﬁcant difference in lung injury,
assessed byhistological scoring inhMSC treatedpigs versus controls (p=0.063). Therewasnodifference inneu-
trophil counts between hMSC-treated pigs and controls. Within 4 h, there was no difference in the levels of IL-10
and IL-8 pre- and post-treatment with hMSC. In addition, there was no difference in hemodynamics, lung me-
chanics or arterial blood gases between hMSC treated animals and controls. Subsequent studies are required to
determine if the observed decrease in inﬂammatory transcription factors will translate into improvement in in-
ﬂammation and in physiological parameters over the long term.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Acute lung injury (ALI)
Mesenchymal stem cells (MSC)
Oleic acid (OA)
Nuclear factor-light chain enhancer of activated
B cells (NF-κB)
Pig1. Introduction
Acute respiratory distress syndrome (ARDS) is characterized by re-
fractory hypoxemia in patients with bilateral lung inﬁltrates. The Berlin
deﬁnition of ARDS is based on the degree of hypoxemia: mild
(200 mm Hg PaO2/FiO2 ≤ 300 mm Hg), moderate (100 mm Hg PaO2/
FiO2 ≤ 200 mm Hg), and severe (PaO2/FiO2 ≤ 100 mm Hg). In addition,
the condition must develop within one week of a known clinical insult
or new/worsening respiratory symptoms. Bilateral opacities on chest
imaging that is not fully explained by effusions, lobar/lung collapse or
nodules and the respiratory failuremust not be fully explained by cardi-
ac failure or ﬂuid overload (Ranieri et al., 2012). A National Institutes of
Health study estimated the incidence of ARDS to be 75/100,000ealth, School of Medicine and
kins Research Institute, Robin
50, Australia.
ley).
. This is an open access article underpopulation in the USA, while in Australia the incidence is estimated at
30/100,000 admissions (Ware and Matthay, 2000).
ARDSmay be caused by direct or indirect injuries to the lung includ-
ing aspiration of gastric contents and sepsis (Petty and Ashbaugh,
1971). The early phase of lung injury is characterized by epithelial and
endothelial cell damage leading to a compromised alveolar-capillary
barrier and exudation of ﬂuid into the alveolar space, followed by inﬁl-
tration of inﬂammatory cells such as neutrophils. Progression from
acute lung injury (ALI) to a ﬁbro-proliferative phase observed 5–
7 days after the injury may be reversible or persistent (Leaver and
Evans, 2007).
Many strategies have been directed at reducing lung injury and aug-
menting tissue repair in ALI/ARDSwith limited beneﬁcial outcomes. Low
tidal volume ventilation and prone positioning have proven to be effec-
tive in reducing mortality (Slutsky and Ranieri, 2000; Guerin et al.,
2013). However, a randomised control trial of “Conventional ventilatory
support vs extracorporeal membrane oxygenation (ECMO) for severe
adult respiratory failure (CESAR)” showed that ECMO had limited suc-
cess in preventing lung injury (Ware and Matthay, 2000; Peek et al.,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
26 Y. Moodley et al. / Stem Cell Research 17 (2016) 25–312006). Given the signiﬁcant mortality associated with ARDS, alternative
therapies aimed at reducing lung injury are needed.
Stem cell therapy has raised the possibility of augmenting lung re-
pair and restituting damaged lung tissue. Human bonemarrow derived
mesenchymal stem cells (hMSC) have improved a variety of animal
models of acute lung injury and ex vivo models of human lung injury
(Ortiz et al., 1999; Lee et al., 2009; Asmussen et al., 2014). Although
there have been signiﬁcant advances inMSC therapy including the com-
mencement of clinical trials, there are still critical areas that need fur-
ther elucidation. There is a paucity of studies testing MSC in large
animal models of ALI. In addition, there is conﬂicting data regarding
the onset of beneﬁt ofMSC. Several studies have shown beneﬁcial phys-
iological effects of MSC at time points of 24–48 h post-infusion
(Asmussen et al., 2014; Devaney et al., 2015), whilst Rojas et al.
(2014) showed beneﬁcial effects within 2 h of MSC infusion (Rojas et
al., 2014). Therefore, determining the early effects of MSC on inﬂamma-
tion and lung physiology in a large animal model of ALI would inform
clinical studies about the timelines to expect improvement and the im-
pact of MSC on the early pathogenesis of the disease.
There are several proposed mechanisms by which hMSC act includ-
ing the release of anti-inﬂammatory mediators such as nitric oxide, IL-
1R antagonist, angiopoietin and tumour necrosis factor-inducible gene
(TSG-6) (Moodley et al., 2013). Recently, MSC were shown to release
exosomes including donatingmitochondria that then improve the ener-
getics of damaged tissue thus augmenting repair (Islam et al.). Based on
the pathogenesis of ALI/ARDS and themechanisms of action of MSC, we
hypothesized that MSC would improve the early inﬂammatory and
physiological changes in this condition. In this study, we treated an
oleic acid (OA) induced-ventilatory pig model of ALI with hMSC and
measured physiological and inﬂammatory outcomes during the initial
4 h after treatment.
2. Materials and methods
2.1. Preparation of hMSC
Human MSC were isolated from donor bone marrow as previously
described (Herrmann et al., 2012), and culture expanded in Dulbecco's
modiﬁed eagle medium (DMEM; Gibco, Life Technologies) containing
10% fetal bovine serum (FBS;HyClone, Thermo Scientiﬁc). Bonemarrow
forMSCmanufacturingwas collected under the approval from the Royal
Perth Hospital Ethics Committee for clinical therapy and the need for
consent to use the cells for research was waived because the cells
manufactured were surplus to requirements.
The batch of hMSC used in our study expressed the cell surface
markers CD105, CD90 and CD73, but not CD45, CD34, CD11b, and the
human leucocyte antigen (HLA)-DR. Cells were harvested at P3 and
cryopreserved at 5 × 106 cells/ml in 10% dimethyl sulfoxide (DMSO;
Wakchemi), 10% porcine serum (HyClone, Thermo Scientiﬁc) and 80%
sodium chloride solution (0.9%) in OriGen cryogenic bags using a con-
trolled rate freezer. Cells were then stored at−196 °C in vapour nitro-
gen. Cell aliquots containing 40 × 106 cells along with control bags
(same vehicle but without cells) were prepared at the Cell and Tissue
Therapies WA (CTTWA) facility, cryopreserved in cryobags, shipped
on dry ice to the University ofManitoba and stored at−80 °C in a secure
fridge.
2.2. Ventilation of pigs
After receiving approval from the University of Manitoba Animal
Care Ethics Committee (submitted, Sep. 2012), a total of 12 farm bred
female pigs (20–22 kg) were fasted overnight with free access to
water. An intramuscular injection of ketamine, midazolam and atropine
(10/0.1/0.02 mg/kg) was given for sedation. Anaesthesia was induced
with isoﬂurane by inhalation via a nosecone. The animals were
intubated with a 6.0 cuffed endotracheal tube and mechanicallyventilated with a tidal volume = 10 ml/kg, inspired oxygen concentra-
tion = 50%, positive end-expiratory pressure (PEEP) = 5 cm H2O and
respiratory rate adjusted to maintain PaCO2 in the normal range. Anaes-
thesiawasmaintainedwith 1.5 to 2MAC Isoﬂurane during surgical prep-
aration. An intravenous infusion of Ringer's Lactate (10 ml/kg/h) was
established in an ear vein. Through a cut-down, a 5 ft SwanGanz catheter
was ﬂoated into the pulmonary artery via the external jugular vein to
measure pulmonary artery pressure, pulmonary capillary wedge pres-
sure, right atrial pressure and cardiac output by thermodilution in tripli-
cate. A femoral artery cannulawas placed for continuous arterial pressure
measurement and blood gas sampling. A femoral venous cannula was
advanced in the IVC above the diaphragm for OA administration.
Anaesthesia was then switched to a continuous infusion of propofol/
ketamine/rocuronium, 10/2.5/0.5 mg/kg/h to allow for ventilation with
an Esprit ® ventilator, which ensured more precise control of tidal vol-
ume, PEEP and respiratorymechanic measurements for the experimen-
tal period. Muscle relaxation was required to prevent spontaneous
ventilator efforts during low tidal volume ventilation which interfere
with accurate measurements of lung mechanics. The animal was
allowed to stabilize for 15 min after surgical preparation, then baseline
hemodynamics, arterial blood gases and lung function (peak and mean
airway pressures, total respiratory system compliance, by interrupter
method, and dead space) were determined.
2.3. Oleic acid induced injury
ALI was then induced with a well-established protocol (Froehlich et
al., 2008). OAwas infused at 0.2 ml/kg/h until static respiratory compli-
ance decreased by at least 40% and arterial PaO2 decreased to
b100 mm Hg at an FIO2 of 50%. Dopamine was infused at 5–10 mcg/kg/
min during OA infusion to maintain arterial blood pressure N 60 mm Hg,
then discontinued. When a stable injury had been achieved, (no further
change in blood gases or lung compliance for 15 min) ventilation was
maintained with a low tidal volume strategy (VT = 7 ml/kg, PEEP 10,
FiO2 50%) for the duration of experiments. The animals were allowed
to stabilize for 1 h and measurements repeated. The animals were
then randomly assigned to a sham treatment group (n = 5) or hMSC
group (n = 6).
2.4. MSC administration
The dose of MSC of 2 × 106 cells/kg administered intravenously was
based on our studies in other disease cohorts (Forbes et al., 2014). In
preparation for infusion, the cryobag was thawed in a water bath of
sterile saline at 37 °C. An equal volume of sterile Ringer's Lactate was
added to the bag to stabilize the cells. The cells (2 × 106 cells/kg) or ve-
hicle control were infused immediately following preparation over
10 min. DMSO, used in the cryopreservation of the MSC was infused
with the cells and DMSO present in the vehicle control was adminis-
tered to controls in equivalent volumes to the experimental group but
without the cells. Cell viability was assessed using the Vi-Cell XR cell
analyser (trypan blue based determination) post cryopreservation and
in our laboratory was 87% viability.
Blood gases and lung function measurements were determined im-
mediately after infusion and then hourly for 4 h. Lung oedema ﬂuid as-
pirate samples were obtained by gentle suction of a soft catheter
wedged into a distal airway at baseline OA injury (1 h post OA infusion)
and at 4 h of ventilation post lung injury. Samples were centrifuged at
3000 g for 10 min and the supernatant stored at−80 °C. The animals
were sacriﬁced using Euthanyl 100 mg/kg with lung inﬂation main-
tained at 10 cm PEEP.
2.5. Histology and lung aspirate
Lung tissue samples were obtained from upper, middle and lower
lobes and ﬁxed in formalin. The lungs were then removed en bloc,
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27Y. Moodley et al. / Stem Cell Research 17 (2016) 25–31weighed and dried to determine the wet:dry weight ratio. Cytokine
levels were assessed in paired aspirate samples obtained at time zero
and 4 h post-MSC transfer. Following centrifugation, each was quanti-
ﬁed in triplicate using Duoset ELISAs (R&D Systems) following the
manufacturer's protocols but optimized to provide sensitivity of
16 pg/ml (IL-8) and 6 pg/ml (IL-10). Inter-assay variability was 5–10%.
ELISA for measurement of cytokine responses in primary culture was
done (Stefura et al., 2008).
Formalin-ﬁxed parafﬁn-embedded pig lung tissuewere stainedwith
hematoxylin and eosin and examined under a light microscope (×400
magniﬁcation). About 120 random areas (about 40 random area for
each upper, middle and lower right lobe for each sample) were evaluat-
ed. Histopathological lung injury scoring analysis was performed ac-
cording to the ATS Workshop Report methodology (Matute-Bello et
al., 2011; Voelker et al., 2014). The degree of microscopic injury was
scored by two raters based on the following variables: neutrophils in
the alveolar space, neutrophils in the interstitial space, hyaline mem-
branes, proteinaceous debris ﬁlling the airspace and alveolar septal
thickening. Each element was graded according to a 3-point scale de-
scribed (Table 1), and the result was expressed as a mean of the total
score of the two raters. All counts and scores were done in a blinded
fashion.
2.6. Immunoﬂuorescence
Immunoﬂuorescence of NF-κB was examined in formalin ﬁxed pig
lung tissues sections. Brieﬂy, following deparafﬁnization and perme-
ation with a PBS-Triton (0.1%, 5 min) solution, and saturation of non-
speciﬁc sites with BSA (5%, 30 min), cells were incubated with primary
antibodies of NF-κB (Abcam) overnight in a humidiﬁed chamber at 4 °C.
Conjugated secondary antibodies were used at a dilution of 1:2000.
Slides were mounted in Prolong-gold with DAPI (ProLong® Gold
antifade regent with DAPI, Life Technologies). To take a picture of the
immunoﬂuorescence, we used the automatic slide scanner microscope
(Olympus VS 120-L). The analysis of nuclear translocation was per-
formed using the plugin (JACoP) for imageJ. Picture threshold used for
the analyses was identical for all images.
2.7. Statistics
We used repeated measures ANOVA to demonstrate differences be-
tween OA treated and OA+MSC pigs. A p-value of b0.05, corrected for
repeated measures was regarded as signiﬁcant. Random effects linear
regression models with maximum likelihood estimation (MLE) were
used to investigate differences in injury scores (2 raters) post injury be-
tween OA andOA+MSC groups, aswell differences in the pattern of IL-
8 and IL-10 over time between the two groups via the interaction of
group and time (pre and 4 h post injury). Injury scores were analysed
with repeated measures to account for scoring by two raters. TheTable 1
Lung injury scoring system.
Parameter Score per ﬁeld
0 1 2
A. Neutrophils in the alveolar space none 1–5 N5
B. Neutrophils in the interstitial space none 1–5 N5
C. Hyaline membranes none 1 N1
D. Proteinaceous debris ﬁlling the airspaces none 1 N1
E. Alveolar septal thickening b2× 2–4× N4×
Score= [(20 × A)+ (14 × B)+ (7 × C)+ (7 × D)+ (2 × E)] / (number of ﬁelds × 100).
Neutrophils scores were calculated using data obtained from lung injury scoring. Brieﬂy,
neutrophils are counted in the alveolar airspaces and interstitium. If neutrophils are not
visible within the ﬁeld, a score of zero is recorded for that ﬁeld. One to ﬁve neutrophils
give a score of one, and more than ﬁve neutrophils give a score of two. The result was
expressed as amean of the sum of individual scores for both alveolar space and interstitial
space neutrophils. Ta
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ed using random effects linear regression with MLE. Differences in the
association between OA and OA + MSC groups were tested using the
three way interaction of group, neutrophil count and time. Analysis
was conducted using Stata (StataCorp. 2013. Stata Statistical Software:
Release 13. College Station, TX: StataCorp LP).
3. Results
3.1. Respiratory and hemodynamic parameters
A similar degree of lung injury was induced in both OA and hMSC
groups. Total respiratory system compliance decreased by 50% with
OA injury and was associated with a PaO2 nadir of 99 (3) mm Hg and
PaO2/FiO2 ratio 198 (5) in the control OA group vs a PaO2 nadir of 90
(10) mm Hg and PaO2/FiO2 ratio of 181 (20) in the hMSC group. These
values correlatewith amoderate ALI score using the Berlin classiﬁcation
(Ranieri et al., 2012). This degree of lung injurywas chosen to ensure vi-
ability for the duration of the study period. Post nadir, with PEEP in-
creased to 10 cm H2O, PaO2 increased to 140 mm Hg in both groups
with no change in respiratory system compliance (Tables 2 and 3), dem-
onstrating recruitability in themodel. The increase in PaO2 over the sub-
sequent 4 h with minimal improvement in respiratory system
compliance suggests the presence of a signiﬁcant hypoxic pulmonary
vasoconstrictor response, despite the presence of signiﬁcant lung inﬁl-
trates, as previously demonstrated in this porcine model (Graham et
al., 2011).
There were no differences in airway pressures, arterial blood gases,
lung mechanics, or hemodynamics between control and hMSC treated
pigs at baseline, post OA injury, post hMSC administration or in the sub-
sequent 4 h studied (Tables 2 and 3). Left lungwet:dryweight ratio was
5.2 (0.4) and 5.8 (0.8) in control and hMSC treated groups respectively,
corroborating themodest degree of lung injury. No adverse events were
documented with the administration of hMSC, with no subsequent
changes in either temperature or any hemodynamic parameter over
those seen with OA administration alone.
3.2. There is a reduction in NF-κB nuclear translocation following hMSC
treatment
NF-κB is an important transcription factor for the activation of sever-
al inﬂammatory pathways. We examined NF-κB nuclear translocation
to determine if therewas a change in the expression of this transcription
factor following hMSC treatment. The NF-κB positive nucleus was
assessed by counting the number of positive cells on ﬂuorescence mi-
croscopy of lungs obtained at 4 h post-hMSC infusion. NF-κB nuclear
translocation was signiﬁcantly reduced in lungs of pigs treated with
hMSC as compared to controls (p = 0.04; Fig. 1).
3.3. There were no signiﬁcant changes in lung injury following hMSC
Noting the fall in NF-κB nuclear translocation, we investigated the
role of hMSC in treating lung injury and inﬂammation. The composite
lung injury assessment was made by scoring histological sections of
the lung following 4 h post-hMSC treatment. The composite lung injury
score demonstrated a numerical reduction in lung injury in hMSC treat-
ed pigs versus controls but this did not reach statistical signiﬁcance
(p = 0.063; Fig. 2).
Neutrophilic inﬂammation was also assessed by counting neutro-
phils on histological sections of lung. There were no signiﬁcant differ-
ences in the composite neutrophil counts which included upper,
middle and lower lobes between control and hMSC groups (p = 0.36;
Fig. 3a). There was a trend towards reduced alveolar neutrophil count
in the upper lobes in hMSC group versus controls, however, this was
not statistically signiﬁcant (p = 0.07; Fig. 3b).
Fig. 1. There is a signiﬁcant fall in NF-κB following OA + MSC versus OA alone. Immunoﬂuorescence shows that NF-κB nuclear translocation in the lung tissue. A: OA injured lung. B:
OA + MSC injured lung. C: The NF-κB positive nuclei percentage was calculated by counting at least 200 DAPI-positive cells per sample were counted (×400 magniﬁcation). Red is NF-
κB and blue is DAPI. There is a signiﬁcant decrease in NF-κB positive nuclear cells in hMSC treated pigs versus controls.
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There was no signiﬁcant difference detected in the change in aspi-
rate IL-10 levels or IL-8 levels over time between hMSC groups and con-
trols (p = 0.18 and p = 0.23 respectively; Fig. 4). The three way
interaction of time, group and neutrophils in the IL-8model was almost
signiﬁcant (p = 0.06). This indicates that the change in the slope from
pre to post test in the control group differs from the change in the
slope from pre to post in the stem cell group. This suggests a close asso-
ciation in the change of IL-8 and neutrophils.4. Discussion
The present study characterises the early effects and safety proﬁle of
hMSC therapy in a large animal model of ALI. After 4 h of treatment, we
have demonstrated that hMSC reduced tissue NF-κB, an important tran-
scription factor that mediates inﬂammation while no signiﬁcant effects
on hemodynamics, lung mechanics, gas exchange, inﬂammatory medi-
ators or lung injury scores were evident. These data suggest that hMSC
therapy is safe over the short term. Subsequent studies are required to
determine if the observed decrease in inﬂammatory transcription fac-
tors translates into improvements in inﬂammation and in physiological
parameters over the long term.
The beneﬁcial effects of MSC have been described in several animal
models (Rojas et al., 2014; Curley et al.). In two studies using a rat
model of ventilator-induced lung injury, there were improvements in
lung injury within 4 h of MSC treatment (Chimenti et al., 2012; Hayes
et al., 2015). However, in ALI/ARDS there is a relative paucity of cell
therapy studies in large animal models. Pre-clinical studies in large an-
imal models are more informative about potential efﬁcacy as compared
to small rodents, with their signiﬁcant differences in biology andFig. 2. There is a numerical reduction in the inﬂammatory score between OA and OA +MSC. T
tissue sections obtained 4 h post-hMSC treatment and controls. (c) There was a reduction in thphysiology to humans. Our results suggest that the early beneﬁts seen
in small animal models are not evident in a larger porcine model.
There are few studies that reported the physiological parameters in
the early period post stem cell therapy. In a ventilator induced lung in-
jurymodel in rats, MSC improved oxygenation, oxygen alveolar-arterial
gradient, static compliance and microvascular permeability at 48 h
post-treatment. The shorter time-points were not analysed (Curley et
al.). Asmussen et al. (2014) used a cotton smoke inhalation model and
infectionwith Pseudomonas aeruginosa to determine if hMSCwould im-
prove a sheep model of pneumonia. At 24 h post-hMSC treatment, pul-
monary artery pressures were reduced and PaO2/FIO2 ratio increased
with no differences in airway pressure between controls and hMSC
treated sheep. Notably there was no difference in any physiological pa-
rameters between controls and hMSC treated groups at time-points be-
fore 24h (Asmussen et al., 2014). Both these studies are in-keepingwith
our ﬁndings of no physiological changes at 4 h. In contrast, Rojas et al.
(2014) found that autologous CD45 negative bonemarrowmononucle-
ar cells (BMC) signiﬁcantly reduced pulmonary vascular resistance and
improved oxygenation at 2 h post-treatment in an endotoxin-induced
porcine model of lung injury. The BMC preparation would include
MSC and vascular cells. The difference in injury model and cell therapy
chosen may explain the difference between these results and the pres-
ent study, despite the use of pigs in both studies. These studies support
the need for monitoring the effect of MSC at longer time-points
(Asmussen et al., 2014; Rojas et al., 2014; Curley et al.).
We used a well characterized method of OA induced lung injury in
ventilated pigs. OA (cis-9-octadecenoic acid) is the most common free
fatty acid in mammals, comprising 60% of the free fatty acid pool and
is, through as yet unknown mechanism, directly toxic to endothelial
cells within oneminute of administration (Beilman, 1995). It causes ne-
crosis and severe vacuolation of endothelial cells followed by epithelial
injury (Hussain et al., 1998). OA and mechanical injury mimics earlyhe injury score of (a) OA injured lung and (b) OA+MSC injured lung was based on lung
e score for hMSC treated animals but this did not reach signiﬁcance.
Fig. 3. There is a mild reduction in alveolar neutrophils in the upper lobe between OA and OA+ hMSC. Tissue sections obtained from lung were scored for neutrophil inﬁltration of the
alveolar space and interstitium. (a) Therewas no difference in total neutrophil scores between hMSC treated animals and controls across the upper, middle and lower lobe of the lung. (b)
There was a reduction in alveolar neutrophil inﬁltration in the upper lobe of hMSC treated animals versus controls which almost reach signiﬁcance.
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membrane formation leading to the physiological changes including in-
creased capillary permeability, hypoxia from ventilation-perfusion
mismatching and shunting, decreased lung compliance and increased
dead space (Voelker et al., 2014).
Since inﬂammation is reduced by hMSC, we examined the expres-
sion patterns of the transcription factor NF-κBwhich is central to thede-
velopment of inﬂammation and found in high concentrations in ARDS
(Vlahopoulos et al., 1999; Bajwa et al., 2011; Fudala et al., 2011). NF-
κB is a transcription factor found in all cells and constitutes a family of
DNA-binding proteins that are responsible for the gene transcription
of pro-inﬂammatory cytokines, chemokines and adhesion molecules
(Perkins, 2007). NF-κB responds to different stimuli including oxidants
and cytokines (Perkins, 2007). Following activation of cytokine recep-
tors such as tumour necrosis factor associated receptor, the complex ac-
tivates NF-κB inducing kinase (NIK) which results in the
phosphorylation of IκB. The phospho-IκB, destined for the
ubiquitinization/proteosome pathway, dissociates from NF-κB thereby
allowing NF-κB to translocate into the nucleus for gene transcription
(Zhang et al., 2000).
There was a decrease of NF-κB nuclear translocation on immunoﬂu-
orescence of lung tissue at 4 h, in hMSC treated pigs versus untreated
controls. The number of cells with positively staining nuclei for NF-κB
was signiﬁcantly lower in the treatment group compared to controls.
This suggests that the hMSC reduce NF-κB expression within 4 h of
hMSC injection.We did not determine themechanisms of NF-κB reduc-
tion in our model. Studies have suggested that the production of both
transforming growth factor-β and TSG-6 by MSC are shown to reduce
NF-κB and may play a role in our study (Wen et al., 2014).Fig. 4. There is no change in IL-10 and IL-8 levels following hMSC treatment. Cytokines (a) IL-1
hMSC treatment and 4 h post-hMSC treatment. There was no change in IL-10 and IL-8 levels pNoting the reduction inNF-κB nuclear translocation,we assessed the
degree of lung injury by scoring of histological sections at 4 h post-hMSC
infusion. The injury score utilized in this study incorporated hyaline
membrane formation, alveolar septal thickening, debris in the alveolar
spaces and neutrophil inﬁltration (Matute-Bello et al., 2011). These fea-
turesmimic the histologic changes that occurwith ARDS. The difference
in injury scores between controls and hMSC treated pigs did not reach
statistical signiﬁcance.
We separately assessed neutrophil inﬁltration of the lung following
hMSC treatment. Neutrophils are the ﬁrst cells recruited to sites of inju-
ry following the release of chemokines from macrophages, endothelial
and epithelial cells (Leonard and Yoshimura, 1990). These cells release
several mediators such as oxidants and proteinases that have potent
anti-microbial properties but at excessive levels cause bystander dam-
age to normal tissue (Palmgren, 1992). In ALI/ARDS, there are many
lines of evidence that points to an important role for neutrophils in
the pathogenesis of this condition (Curley et al.; Abraham, 2003). In ad-
dition, increased neutrophils in aspirates correlate with reduced surviv-
al (Yang et al., 2003). In our study there was no difference in total
neutrophil inﬁltration of the lung between controls and hMSC treated
animals as determined by histological scores of upper, middle and
lower lobes of lungs at 4 h post treatment. Furthermore,we investigated
the changes in the cytokine IL-8 by ELISA in aspirate since this cytokine
is raised in ARDS and acts as a chemokine for neutrophils (Ware and
Matthay, 2000; Miller et al., 1992), and is consistently the closest asso-
ciation to disease severity and survival in ARDS (Struyf et al., 2005;
Goodman et al., 1996). Therewas no difference in IL-8 between controls
and hMSC treated groups. In addition, there was no difference pre- and
post-hMSC treatment. However, there was a signiﬁcant relationship0 and (b) IL-8 were measured by ELISA in aspirate samples following OA instillation pre-
re-hMSC and 4 h post-MSC treatment.
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trols and hMSC groups fromover time (frombaseline to 4 h) conﬁrming
the association of this cytokine with neutrophil inﬁltration in this
model.
Limitations to our study include a model which may not mimic all
the steps in ALI/ARDS. In addition, this was considered a pilot study, ap-
proved as a safety and feasibility trial by the Ethics Committee. The re-
sults are underpowered due to the limited number of animals
allowed. We conclude that the observed reduction in the inﬂammatory
transcription factor NF-κB, coupled with trends toward decreases in in-
ﬂammation and lung injury provide evidence to warrant further large
animal studies which include a greater number of subjects monitored
for a longer time period to determine if hMSC treatment may provide
a role in the management of ALI/ARDS.
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